EXELIXIS, INC. - 8-K Filing
Exelixis reports Q3 2026 total revenues of $658.7 million, driven by cabozantinib franchise growth. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $EXEL
Read the full article at SEC EDGAR
Part of the story Cloudflare Shares Surge Following Strong Q3 Results and Raised Full-Year Guidance (85 articles)